FENC

Fennec Pharmaceuticals Inc.

Healthcare · $384M market cap

Verdict

We can't put a fair value on FENC right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth1.0% a year✗
Sales growth44.9% a year✓
Free cash flow growth—?
Return on invested capital-23.9%✗

Follow FENC

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Oct 31, 2026: no open-market purchases and 5 other filings (stock awards, tax withholding and similar). Why purchases matter

Other filings

Questions about FENC

Are insiders buying FENC?

Since Oct 31, 2026: no open-market purchases and 5 other filings (stock awards, tax withholding and similar).

How can I check FENC's value myself?

Use the free Sticker Price calculator, already filled with FENC's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →

Similar stocks · Biotechnology

About Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Nov 3, 2026. How the Payback Price works